লোডিং...
Second line chemotherapy and visceral metastases are associated with poor survival in patients with mCRPC receiving (177)Lu-PSMA-617
The purpose of this study was to identify previous treatments and biomarker profile features that prognosticate overall survival (OS) in patients with mCRPC receiving (177)Lu-PSMA-617. Methods: 109 mCRPC patients treated with a median of 3 cycles of (177)Lu-PSMA-617 were included. Data were analyzed...
সংরক্ষণ করুন:
| প্রকাশিত: | Theranostics |
|---|---|
| প্রধান লেখক: | , , , , , , |
| বিন্যাস: | Artigo |
| ভাষা: | Inglês |
| প্রকাশিত: |
Ivyspring International Publisher
2019
|
| বিষয়গুলি: | |
| অনলাইন ব্যবহার করুন: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6691377/ https://ncbi.nlm.nih.gov/pubmed/31410185 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/thno.35759 |
| ট্যাগগুলো: |
ট্যাগ যুক্ত করুন
কোনো ট্যাগ নেই, প্রথমজন হিসাবে ট্যাগ করুন!
|